JP2003516936A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516936A5
JP2003516936A5 JP2001534412A JP2001534412A JP2003516936A5 JP 2003516936 A5 JP2003516936 A5 JP 2003516936A5 JP 2001534412 A JP2001534412 A JP 2001534412A JP 2001534412 A JP2001534412 A JP 2001534412A JP 2003516936 A5 JP2003516936 A5 JP 2003516936A5
Authority
JP
Japan
Prior art keywords
particles
adjuvant
antigen
coated
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516936A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/025854 external-priority patent/WO2001032208A1/en
Publication of JP2003516936A publication Critical patent/JP2003516936A/ja
Publication of JP2003516936A5 publication Critical patent/JP2003516936A5/ja
Pending legal-status Critical Current

Links

JP2001534412A 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン Pending JP2003516936A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/025854 WO2001032208A1 (en) 1999-11-03 1999-11-03 Adjuvanted genetic vaccines

Publications (2)

Publication Number Publication Date
JP2003516936A JP2003516936A (ja) 2003-05-20
JP2003516936A5 true JP2003516936A5 (enExample) 2006-12-28

Family

ID=22273970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534412A Pending JP2003516936A (ja) 1999-11-03 1999-11-03 アジュバント化遺伝子ワクチン

Country Status (14)

Country Link
EP (1) EP1227840B1 (enExample)
JP (1) JP2003516936A (enExample)
CN (1) CN100333794C (enExample)
AT (1) ATE374622T1 (enExample)
AU (1) AU780448C (enExample)
CA (1) CA2389686A1 (enExample)
CY (1) CY1107845T1 (enExample)
DE (1) DE69937258T2 (enExample)
DK (1) DK1227840T3 (enExample)
ES (2) ES2294864T3 (enExample)
IL (2) IL149415A0 (enExample)
NZ (1) NZ518766A (enExample)
PT (2) PT1913957E (enExample)
WO (1) WO2001032208A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1913957T3 (da) * 1999-11-03 2010-05-10 Powderject Vaccines Inc Genetiske adjuvant-vacciner
WO2002094313A2 (en) * 2001-05-18 2002-11-28 Powderject Vaccines, Inc. Vaccine composition
US7566478B2 (en) 2001-07-25 2009-07-28 Nantero, Inc. Methods of making carbon nanotube films, layers, fabrics, ribbons, elements and articles
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
WO2014145906A2 (en) * 2013-03-15 2014-09-18 Phd Preventative Health Care And Diagnostics, Inc. A prefilled medication device, method of making and using the same
EP3983085A4 (en) * 2019-06-12 2023-01-25 Wisconsin Alumni Research Foundation Novel adjuvant for animal and human vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
KR100365986B1 (ko) * 1996-02-09 2003-02-20 스미스클라인 비이참 바이오로지칼즈 에스.에이. 수두대상포진바이러스유전자63생성물에대한백신
AU722326B2 (en) * 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
WO1998046263A1 (en) * 1997-04-14 1998-10-22 University Of Massachusetts Medical Center Saponin adjuvants in combination with dna vaccination
EP1035867A1 (en) * 1997-12-02 2000-09-20 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
CU22740A1 (es) * 1998-09-07 2002-02-28 Ct Ingenieria Genetica Biotech Formulación de ácidos nucleicos y acemanano

Similar Documents

Publication Publication Date Title
EP1322287B1 (en) Microparticles for delivery of the heterologous nucleic acids
JP2025063030A5 (enExample)
Saroja et al. Recent trends in vaccine delivery systems: a review
Chong et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery
O’Hagan et al. Microparticle-based technologies for vaccines
Moser et al. Virosomal adjuvanted antigen delivery systems
Kaurav et al. Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage
CN104027324B (zh) 一种可溶性微针疫苗贴片及其制备方法
JP4601168B2 (ja) 吸着表面を有する微小粒子、それを作製する方法、およびその使用
EP2269642A2 (en) Hcv vaccine compositions
JP2001523729A5 (enExample)
JP2022101576A (ja) スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
Cui et al. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses
JPH11500443A (ja) コクリエート送達ビヒクル
JP2001524533A (ja) 粒子状ワクチン組成物の経皮的送達
JP2003514872A5 (enExample)
Wang et al. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice
Plotkin Six revolutions in vaccinology
Newman et al. Immunological and formulation design considerations for subunit vaccines
Prashant et al. Nanoparticle based tailoring of adjuvant function: the role in vaccine development
Engler et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates
JP2003516936A5 (enExample)
Ha et al. Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination
JP2006502228A5 (enExample)
Mora et al. Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations